- Previous Close
76.40 - Open
76.40 - Bid 79.05 x --
- Ask 79.20 x --
- Day's Range
75.40 - 79.50 - 52 Week Range
60.85 - 106.00 - Volume
613,409 - Avg. Volume
759,354 - Market Cap (intraday)
15.842B - Beta (5Y Monthly) -0.05
- PE Ratio (TTM)
5.02 - EPS (TTM)
15.77 - Earnings Date Nov 8, 2024
- Forward Dividend & Yield 0.25 (0.32%)
- Ex-Dividend Date Jun 25, 2024
- 1y Target Est
--
Deva Holding A.S. manufactures, markets, and sells pharmaceutical products in Turkey. The company provides antineoplastic and immunomodulating agents; dermatological products; sysyemic hormanal preparations; anti-infective and antiparasitic products for systemic use; food supplements; and electrolyte solutions. It also offers products in the areas of urogenital system and sex hormones, blood and blood forming organs, cardiovascular system, musculoskeletal system, nervous system, alimentary tract and metabolism, respiratory system, urinary systems, connective tissue, and sensory organs; and veterinary medicines. In addition, the company offers various products in sterile and non-sterile forms, including liquids, semi-solids, solids, cephalosporins, penicillin, hormone and inhalation products, solid and liquid oncology, animal health products, active pharmaceutical ingredients, ampoules, liquid and lyophilized vials, eye drops, medical ampoules for sterile injectable products, and cologne. It also exports its products to approximately 50 countries. The company was incorporated in 1958 and is based in Istanbul, Turkey. Deva Holding A.S. is a subsidiary of Eastpharma S.à R.L.
www.deva.com.tr3,023
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: DEVA.IS
View MorePerformance Overview: DEVA.IS
Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DEVA.IS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DEVA.IS
View MoreValuation Measures
Market Cap
15.84B
Enterprise Value
19.58B
Trailing P/E
5.02
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.44
Price/Book (mrq)
0.80
Enterprise Value/Revenue
1.78
Enterprise Value/EBITDA
4.72
Financial Highlights
Profitability and Income Statement
Profit Margin
28.68%
Return on Assets (ttm)
6.15%
Return on Equity (ttm)
24.66%
Revenue (ttm)
11B
Net Income Avi to Common (ttm)
3.15B
Diluted EPS (ttm)
15.77
Balance Sheet and Cash Flow
Total Cash (mrq)
2.86B
Total Debt/Equity (mrq)
33.35%
Levered Free Cash Flow (ttm)
-5.53B